Abstract
Objectives Prior observational studies have suggested a potential association between the usual walking pace and migraine. In the present study, we utilized Mendelian randomization (MR) to investigate the presence of causality and elucidate the specific causal relationship between these two variables.
Methods We performed a genome-wide association study on a population of 499,562 individuals of European ancestry, which revealed 34 genetic variants that exhibited a strong association with the usual walking pace. Additionally, we obtained summary statistics for genome-wide association studies on migraine from several sources. To assess the causal estimates, we employed the random effects inverse variance weighted method (IVW) and several other Mendelian randomizations (MR) methods, including MR-Egger, weighted median, Simple mode, Weighted mode, and MR-PRESSO, to confirm the robustness of our results.
Results Our analysis demonstrated a strong causal association between genetically predicted usual walking pace and a decreased risk of migraine, as determined by inverse variance weighted analysis (odds ratio = 0.33; 95% CI = 0.17 to 0.63; P < 0.001). This association was consistently observed across our investigation’s various Mendelian randomization (MR) methods.
Conclusions This study supports a potential causal association between increased walking speed and a decreased risk of migraine.
Highlight
This study used MR to investigate the causal relationship between the usual walking pace and migraine.
A genome-wide association study identified 34 genetic variants strongly associated with the usual walking pace in a European population.
Multiple MR methods confirmed a consistent causal association between genetically predicted usual walking pace and decreased migraine risk.
Increasing walking speed may reduce the risk of migraine.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes